Vital Signs - 12 June 2006


Regular Price: USD 1,500.00

Special Price USD 1,050.00

30% OFF

* Required Fields

Regular Price: USD 1,500.00

Special Price USD 1,050.00


Be the first to review this product

This issue of Vital Signs, released on June 12, 2006, provides a strategic overview of the potential impact of patent expirations of blockbuster drugs and the resulting growth opportunity for generic drugs. Additionally, an emerging company profile is provided on Cell Genesys, a biotechnology company focused on the development and commercialization of cancer therapies. Reimbursement and regulatory news from the FDA and CMS are also provided for the week of May 30 - June 2, 2006.

Table of Contents

Vital Signs - 12 June 2006Patent Expirations and Opportunities for GenericsPatent Expirations and Opportunities for Generics

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.